Loading...
Market
What will be the market share distribution between Eli Lilly and Novo Nordisk in obesity drugs by end of 2025?
2
Resolution / Starting Odds
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Market analysis reports from firms like IMS Health or EvaluatePharma
Story
Eli Lilly's Zepbound Achieves 47% Greater Weight Loss Than Novo Nordisk's Wegovy in Phase 3B Trial
Dec 4, 2024, 11:52 AM
Eli Lilly & Co. has reported that its weight-loss drug Zepbound, also known as tirzepatide, outperformed Novo Nordisk A/S's Wegovy, or semaglutide, in a Phase 3B head-to-head clinical trial. The trial showed that Zepbound led to an average weight loss of 20.2% over 72 weeks, compared to 13.7% for Wegovy. Participants using Zepbound lost 50.3 lbs (22.8 kg), while those on Wegovy lost 33.1 lbs (15.0 kg). This 47% greater relative weight reduction has been highlighted by Eli Lilly as a significant achievement in the treatment of obesity. The results have led to a rise in Eli Lilly's stock price, reflecting investor confidence in the drug's potential.
View original story
Similar markets
More than 50% • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
Outside top 5 • 25%
Top 3 in the sector • 25%
Top 5 in the sector • 25%
Leader in the sector • 25%
Heart disease • 25%
Stroke • 25%
Kidney disease • 25%
Brain disorders • 25%
Pfizer • 25%
Eli Lilly • 25%
Other • 25%
Novo Nordisk • 25%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Eli Lilly outperforms • 25%
Both underperform • 25%
Both perform equally • 25%
Novo Nordisk outperforms • 25%
Novo Nordisk gains market share • 25%
Both gain equally • 25%
Neither gains market share • 25%
Eli Lilly gains market share • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%
Slightly increase • 25%
Significantly increase • 25%
Decrease • 25%
No change • 25%
Viking Therapeutics • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%